Melanoma Tumor Articles & Analysis
6 news found
The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic patient-derived xenograft (PDX) melanoma model, including greater persistence of cytoTIL15 cells in blood and lymphoid organs, superior tumor ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). ...
TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. ...
Details of the poster presentation: Title: cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility Abstract Number: 1008P Session: Investigational Immunotherapy Abstract Summary: Tumor-infiltrating lymphocytes (TILs) have generated promising data in ...
The abstract for the poster describes how Obsidian’s cytoTIL15 product (cytoTIL™ therapy engineered with mbIL15) demonstrates enhanced in vivo performance in the absence of IL-2, paving the way for more durable efficacy and improved safety in patients with solid tumor malignancies, and has been published in Molecular Therapy. Details of the poster: Title: ...
The research team examined TCR convergence in a set of 85 melanoma tumor biopsies and discovered that convergent TCRs were abundant within tumor, but not in the peripheral blood of healthy donors. ...